This well-conducted review concluded that zanamivir and oseltamivir were effective in reducing symptom duration, but the clinical significance of the modest effect sizes was debatable. Evidence relating to complication rates and adverse events was inconsistently reported across trials; from the evidence available, there was limited impact of either drug. The review's conclusions are likely to be reliable.
The majority of included trials recruited healthy adults or at-risk populations (those with comorbid conditions and the elderly). Where reported, participants' age ranged from one to 99 years, the proportion of males ranged from 21 to 99%, and the delay from onset of symptoms to initiation of treatment was up to 36 or 48 hours. Most included trials defined influenza-like illness; the definition varied across trials and some did not specify a temperature.
Two reviewers independently assessed studies for inclusion. Any disagreement was resolved by consensus or a third reviewer.
Assessment of study quality
The quality of RCTs was assessed by one reviewer using the following criteria: randomisation; allocation concealment; blinding; reporting of eligibility criteria; recruitment of a representative population; comparability of groups at baseline; use of a power calculation; and losses to follow-up. Results were checked by a second reviewer; disagreement was resolved by consensus or a third reviewer.
Data extraction
For dichotomous outcomes, event rates were extracted to enable the calculation of odds ratios (ORs) with 95% confidence intervals (CIs). For continuous outcomes, the median and standard deviation (SD) were extracted to enable the calculation of median differences with 95% confidence intervals. Where standard errors (SEs) of the medians were not available, they were estimated from 95% confidence intervals using the delta method. Pharmaceutical companies were contacted for additional data.
Data were extracted by one reviewer and checked by a second reviewer. Any disagreement was resolved by consensus or a third reviewer. Pooled odds ratios and weighted median differences (WMDs), with 95% confidence intervals, were calculated using a random-effects model where there were more than four trials, otherwise a fixed-effect model was employed. Heterogeneity was assessed using the X 2 test and I 2 statistic. Using continuous outcomes, an indirect comparison was undertaken using placebo as the common comparator.
Subgroup analyses were performed on healthy adults, children, at-risk, and elderly populations. Separate analyses were conducted for those with influenza-like illnesses (intention-to-treat) and those with confirmed influenza.
Results of the review
Twenty-nine RCTs (n=15,096 participants) were included in the review. Methodological quality varied between trials. Twenty-five trials were double-blinded. Thirteen trials reported an appropriate method of randomisation. Only eight trials reported allocation concealment. The duration of follow-up ranged from five to 28 days; only 15 trials had over 95% follow-up.
Comparison with placebo
Zanamivir significantly reduced the median time to symptom alleviation in healthy adults with influenza-like illnesses (WMD -0.57 days, 95% CI -1.07 to -0.08; six RCTs), and the overall at-risk population (WMD -0.98 day; 95% CI -1.84 to -0.11; seven RCTs).
Oseltamivir significantly reduced the median time to symptom alleviation in healthy adults with influenza-like illnesses (WMD -0.55 days, 95% CI -1.05 to -0.14; four RCTs), but not the overall at-risk population (WMD -0.59 days, 95%CI -1.70 to 0.54; three RCTs).
No significant heterogeneity was observed for these outcomes. The limited evidence available for influenza-related complication rates, and the adverse events associated their use, showed little overall impact of either drug on these outcomes. Results for time to normal activity, for those infected with influenza, and for a range of patient subgroups were also reported.
Indirect analysis of interventions:
Oseltamivir had a higher probability of being the better treatment for healthy adults, and zanamivir for at-risk populations.
Cost information
Cost-effectiveness estimates were more favourable in at-risk populations compared with healthy populations. For atrisk populations, the incremental cost-effectiveness ratio estimates were robust for a wider range of alternative assumptions (below £20,000 per quality-adjusted life-year for most scenarios).
